GGrantIndex
Sort

326,823 grants matching clinical trial

Clinical Trials of Parainfluenza and Respiratory Syncytial Virus Vaccines

$2,209,409
Brian Murphy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

Chicago WIHS Consortium V (CWC)

$2,209,223
Mardge H Cohen · Hektoen Institute For Medical Research · U01 · FY2016 · AI

The Pacific Northwest Prostate Cancer SPORE

$2,209,204
Peter S Nelson · Fred Hutchinson Cancer Center · P50 · FY2024 · CA

The Johns Hopkins Translational Science Team for the ET-CTN

$2,209,015
Michael A. Carducci · Johns Hopkins University · UM1 · FY2018 · CA

Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies

$2,208,763
Pamela J Bjorkman · California Institute Of Technology · P01 · FY2023 · AI

Flavivirus Infections: Pathogenesis and Prevention

$2,208,691
Alan L Rothman · Univ Of Massachusetts Med Sch Worcester · P01 · FY2009 · AI

Alzheimer's Disease Research Center

$2,208,597
Mary Sano · Icahn School Of Medicine At Mount Sinai · P50 · FY2018 · AG

Molecular Genetics Of Heritable Human Disorders

$2,208,533
Janice Chou · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2024 · HD

Developmental and Hyperactive Ras Tumor (DHART) SPORE

$2,208,392
David W. Clapp · Indiana University Indianapolis · U54 · FY2024 · CA

PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study

$2,208,081
Meredith Hay · University Of Arizona · U01 · FY2023 · AG

SPORE: Targeted Therapies for Glioma

$2,207,927
Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2023 · CA

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer

$2,207,890
Roy S Herbst · Yale University · P50 · FY2020 · CA

Interleukin-15 Production for Treatment of Patients with Metastatic Malignancy

$2,207,796
Thomas Waldmann · Division Of Basic Sciences - Nci · ZIB · FY2012 · CA

IL-2IL-15 Cytokine Receptor: Implications for Cancer Therapy and Vaccine Design

$2,207,796
Thomas Waldmann · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA

Ancillary: Inflammation/Oxidation, Omega-3's, & Post-Op AFiB & Cognitive Decline

$2,207,492
Dariush Mozaffarian · Brigham And Women'S Hospital · RC2 · FY2009 · HL

AAV Gene Therapy for Lipid Disorders

$2,207,309
James M Wilson · University Of Pennsylvania · P01 · FY2019 · HL

Center for the Biologic Basis of Oral/Systemic Disease (CBBOSD)

$2,207,122
Jeffrey L Ebersole · University Of Kentucky · P20 · FY2010 · RR

Alzheimer's Prevention Initiative ADAD Colombia Trial

$2,207,066
Eric M Reiman · Banner Health · R01 · FY2018 · AG

Optimizing Care for Older Adults through Thyroid Hormone Deprescribing

$2,206,807
Maria Papaleontiou · University Of Michigan At Ann Arbor · RF1 · FY2025 · AG

Biomarkers of Cognitive Decline among Normal Individuals: the BIOCARD cohort

$2,206,720
Marilyn S Albert · Johns Hopkins University · U01 · FY2012 · AG

Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).

$2,206,711
Beth Diane Kirkpatrick · University Of Vermont & St Agric College · P20 · FY2020 · GM

DTMI-Center for Thrombotic and Hemostatic Disorders

$2,206,682
Bruce Alan Sullenger · Duke University · U54 · FY2013 · HL

The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma

$2,206,679
Laura Beretta · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA

Alzheimer's Disease Cooperative Study

$2,206,643
Howard Feldman · University Of California, San Diego · U19 · FY2017 · AG

Effects of Coenzyme Q10 in Parkinson Disease-Phase 3

$2,206,627
Weill Medical College Of Cornell Univ · U01 · FY2005 · NS